{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:10:48Z","timestamp":1760055048939,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,3,1]],"date-time":"2005-03-01T00:00:00Z","timestamp":1109635200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["M\u00e9decine et Maladies Infectieuses"],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1016\/j.medmal.2004.11.004","type":"journal-article","created":{"date-parts":[[2005,3,17]],"date-time":"2005-03-17T16:24:01Z","timestamp":1111076641000},"page":"135-140","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Tol\u00e9rance et interactions m\u00e9dicamenteuses des traitements anti-VIH et anti-VHC"],"prefix":"10.1016","volume":"35","author":[{"given":"T.","family":"Galp\u00e9rine","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Merle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"de Truchis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Perronne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.medmal.2004.11.004_bib1","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/S0399-077X(03)00022-2","article-title":"Co-infection VIH-VHC \u00e0 l'h\u00f4pital. Enqu\u00eate nationale juin 2001","volume":"33","author":"Salmon-C\u00e9ron","year":"2003","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.medmal.2004.11.004_bib2","first-page":"B303","article-title":"Traitement de l\u2019h\u00e9patite C","volume":"26","year":"2002","journal-title":"Gastroenterol Clin Biol"},{"key":"10.1016\/j.medmal.2004.11.004_bib3","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1097\/00002030-200204120-00001","article-title":"Care of patients with chronic hepatitis C and HIV co-infection: recommendations from the HIV\u2013HCV International Panel","volume":"16","author":"Soriano","year":"2002","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2004.11.004_bib4","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1097\/00002030-200311070-00002","article-title":"Update on chronic hepatitis C in HIV\/HCV-coinfected patients: viral interactions and therapy","volume":"17","author":"Brau","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2004.11.004_bib5","unstructured":"Perronne C, Carrat F, Bani-Sadr F, Pol S, Rosenthal Lunel F, et al. Final Results of ANRS HC02-RIBAVIC: A randomized controlled trial of pegylated-interferon-alfa-2b plus ribavirin vs interferon-alfa-2b plus ribavirin for the initial treatment of chronic hepatitis C in HIV Co-infected patients. 11th Conference on retroviruses and opportunistic infections. San Francisco 2004, abstract 117LB."},{"key":"10.1016\/j.medmal.2004.11.004_bib6","unstructured":"Torriani FJ, Rockstroh J. Rodriguez-Torres, Lissen E, Gonzalez J, Lazzarin A et al. Final results of APRICOT: A randomized, partially blinded, international trial evaluating peginterferon-alfa-2a + ribavirin vs interferon-alfa-2a + ribavirin in the treatment of HCV in HIV\/HCV Co-infection. 11th Conference on retroviruses and opportunistic infections. San Francisco 2004, abstract 112."},{"key":"10.1016\/j.medmal.2004.11.004_bib7","unstructured":"Chung R. A randomized, controlled trial of PEG-Interferon-alfa-2a plus ribavirin vs interferon-alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-Co-infected Persons: Follow-up Results of ACTG A5071. 11th Conference on retroviruses and opportunistic infections. San Francisco 2004. Abstract 110."},{"key":"10.1016\/j.medmal.2004.11.004_bib8","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1002\/hep.510260231","article-title":"Tolerance and efficacy of oral ribavirin treatment of chronic hepatitis C: a multicenter trial","volume":"26","author":"Bodenheimer","year":"1997","journal-title":"Hepatology"},{"key":"10.1016\/j.medmal.2004.11.004_bib9","doi-asserted-by":"crossref","first-page":"S315","DOI":"10.1086\/376911","article-title":"Anemia in the treatment of hepatitis C virus infection","volume":"37","author":"Sulkowski","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib10","first-page":"168","article-title":"Hepatitis C\/HIV coinfection: clinical management issues","volume":"2","author":"Poles","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib11","first-page":"2802","article-title":"A preliminary study of erythropoietin for anemia associated with ribavirin and interferon-alpha","volume":"96","author":"Talal","year":"2001","journal-title":"J Gastroenterol"},{"key":"10.1016\/j.medmal.2004.11.004_bib12","doi-asserted-by":"crossref","first-page":"2895","DOI":"10.1097\/00002030-200012220-00011","article-title":"Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection","volume":"14","author":"Den Brinker","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2004.11.004_bib13","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/00126334-200303010-00004","article-title":"Severe hepatotoxicity during combination antiretroviral treatment: incidence, liver histology, and outcome","volume":"32","author":"Puoti","year":"2003","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.medmal.2004.11.004_bib14","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S0166-3542(01)00184-X","article-title":"Management of hepatitis C in HIV-infected persons","volume":"52","author":"Rodriguez-Rosado","year":"2001","journal-title":"Antiviral Res"},{"key":"10.1016\/j.medmal.2004.11.004_bib15","doi-asserted-by":"crossref","first-page":"2149","DOI":"10.1097\/00002030-200111090-00010","article-title":"Long-term efficacy of combination therapy with interferon-alpha 2b and ribavirin for severe chronic hepatitis C in HIV-infected patients","volume":"15","author":"Landau","year":"2001","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2004.11.004_bib16","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/S0168-8278(98)80328-0","article-title":"Insulin-dependent diabetes mellitus during alpha-interferon therapy for chronic viral hepatitis","volume":"28","author":"Fabris","year":"1998","journal-title":"J Hepatol"},{"key":"10.1016\/j.medmal.2004.11.004_bib17","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1086\/374838","article-title":"Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users","volume":"36","author":"Howard","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib18","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(98)04793-X","article-title":"Treatment with interferon-alpha in patients with chronic hepatitis and mood or anxiety disorders","volume":"354","author":"Pariante","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2004.11.004_bib19","first-page":"17","article-title":"The clinical pharmacology of ribavirin","volume":"19","author":"Glue","year":"1999","journal-title":"Semin Liver Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib20","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1097\/00002030-200305020-00008","article-title":"Didanosine, interferon-alfa and ribavirin: a highly synergistic combination with potential activity against HIV-1 and hepatitis C virus","volume":"17","author":"Klein","year":"2003","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2004.11.004_bib21","unstructured":"Fleischer R, Boxwell D, Sherman KE. Evidence suggestive of mitochondrial toxicity in HIV\/HCV co-infected patients receiving ribavirin and didanosine. 10th Conference on retroviruses and opportunistic infections. Boston 2003, abstract 763."},{"key":"10.1016\/j.medmal.2004.11.004_bib22","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(00)04920-5","article-title":"Mitochondrial toxic effects and ribavirin","volume":"357","author":"Kakuda","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2004.11.004_bib23","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1016\/S0140-6736(00)04921-7","article-title":"Mitochondrial toxic effects and ribavirin","volume":"357","author":"Salmon-C\u00e9ron","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2004.11.004_bib24","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00042560-199611010-00005","article-title":"A phase-I study of the safety, pharmacokinetics, and antiviral activity of combination didanosine and ribavirin in patients with HIV-1 disease","volume":"13","author":"Japour","year":"1996","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.medmal.2004.11.004_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S0140-6736(00)03618-7","article-title":"Increased mitochondrial toxicity with ribavirin in HIV\/HCV coinfection","volume":"357","author":"Lafeuillade","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.medmal.2004.11.004_bib26","unstructured":"Hester J, Keiser P, Berggren R. Pancreatitis: an emerging complication of HCV treatment in HIV co-infected patients treated with didanosine\/stavudine containing regimens. Interscience Conference on Antimicrobial Agents and Chemotherapy 2001, Chicago; abstract 739."},{"key":"10.1016\/j.medmal.2004.11.004_bib27","first-page":"283A","article-title":"Concomitant ddI\/d4T and IFN (standard or pegylated)\/ribavirin treatments may induce a high risk of mitochondrial toxicity in HIV\/HCV infected patients (ANRS HC02-Ribavic study)","volume":"36","author":"Hor","year":"2002","journal-title":"Hepatology"},{"key":"10.1016\/j.medmal.2004.11.004_bib28","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1086\/324353","article-title":"Hyperlactatemia and antiretroviral therapy:the Swiss HIV cohort study","volume":"33","author":"Boubaker","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib29","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1086\/323783","article-title":"Symptomatic lactic acidosis in hospitalized antiretroviral-treated patients with human immunodeficiency virus infection: a report of 12 cases","volume":"33","author":"Coghlan","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib30","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1128\/AAC.41.6.1231","article-title":"Effets of drugs on 2'-3'-dideoxy-2'-3'-didehydrothymidine phosphorylation in vitro","volume":"41","author":"Hoggard","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2004.11.004_bib31","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1086\/374837","article-title":"Interferon-ribavirine in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: A Corist-ANRS HC1 Trial","volume":"36","author":"Salmon-ceron","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.medmal.2004.11.004_bib32","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1128\/AAC.39.6.1376","article-title":"Drug interactions with zidovudine phosphorylation in vitro","volume":"39","author":"Hoggard","year":"1995","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2004.11.004_bib33","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1136\/gut.47.5.694","article-title":"Safety and efficacy of interferon-ribavirin combination therapy in HCV-HIV coinfected subjects: an early report","volume":"47","author":"Zylberberg","year":"2000","journal-title":"Gut"},{"key":"10.1016\/j.medmal.2004.11.004_bib34","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1097\/00002030-200001070-00016","article-title":"Effect of interferon and ribavirin on HIV viral load","volume":"14","author":"Landau","year":"2000","journal-title":"AIDS"},{"key":"10.1016\/j.medmal.2004.11.004_bib35","first-page":"140","article-title":"Mitochondrial toxicity of nucleoside analogue reverse transcriptase inhibitors: Lactic acidosis, risk factors and therapeutic options","volume":"1","author":"Brinkman","year":"1999","journal-title":"AIDS Rev."},{"key":"10.1016\/j.medmal.2004.11.004_bib36","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1128\/AAC.46.3.716-723.2002","article-title":"Assessment of mitochondrial toxicity in human cells treated with tenofovir: comparaison with other nucleoside reverse transcriptase inhibitors","volume":"46","author":"Birkus","year":"2002","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.medmal.2004.11.004_bib37","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1093\/infdis\/164.4.646","article-title":"Two drug combinations of zidovudine, didanosine and recombinant interferon-alpha inhibit replication of zidovudine- resistant human immunodeficiency virus type one synergistically in vitro","volume":"164","author":"Johnson","year":"1991","journal-title":"J Infect Dis"}],"container-title":["M\u00e9decine et Maladies Infectieuses"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X0500020X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0399077X0500020X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T00:51:57Z","timestamp":1759971117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0399077X0500020X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2005,3]]}},"alternative-id":["S0399077X0500020X"],"URL":"https:\/\/doi.org\/10.1016\/j.medmal.2004.11.004","relation":{},"ISSN":["0399-077X"],"issn-type":[{"type":"print","value":"0399-077X"}],"subject":[],"published":{"date-parts":[[2005,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tol\u00e9rance et interactions m\u00e9dicamenteuses des traitements anti-VIH et anti-VHC","name":"articletitle","label":"Article Title"},{"value":"M\u00e9decine et Maladies Infectieuses","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.medmal.2004.11.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2005 Elsevier SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}